Johnson & Johnson published the latest results from the MEMBRANE randomized controlled trial, showing that adding middle meningeal artery embolization with TRUFILL™ n-BCA to standard of care reduces recurrence and progression odds and surgical intervention within six months compared to standard of care alone.

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com. Community Guidelines: http://www.jnj.com/social-media-community-guidelines